Pharma channel feed

FDA chief Got­tlieb is build­ing a reg­u­la­to­ry speed­way to ac­cel­er­ate gene ther­a­py de­vel­op­ment

7 years ago
Cell/Gene Tx

Al­ler­gan dou­bles down on NM­DA de­pres­sion drug de­vel­op­ment ef­forts, bag­ging an op­tion to a small mol­e­cule fol­lowup drug

7 years ago
R&D

New­com­er Do­va hus­tles a phar­ma castoff through to an FDA ap­proval, shares sink any­way

7 years ago

Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

7 years ago
R&D

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia block­buster

7 years ago

Al­ler­gan faces fresh woes with Resta­sis patents as Wal­green, re­tail­ers file law­suit over 'an­ti­com­pet­i­tive con­duc­t'

7 years ago

Am­gen, No­var­tis ready to roll as FDA green lights block­buster cam­paign for mi­graine drug — priced at $6,900

7 years ago

Who’s de­lay­ing gener­ic com­pe­ti­tion? FDA pub­lish­es a long list of drug­mak­ers they say gamed the sys­tem

7 years ago

FDA faults IQVIA for er­rors in opi­oid sales da­ta, calls for qual­i­ty re­view

7 years ago

FDA ap­proves first non-opi­oid to treat with­draw­al symp­toms in adults

7 years ago

FDA ex­e­cutes an abrupt about-face as sole-source con­tract for ex-agency chief Mark Mc­Clel­lan draws the spot­light

7 years ago

FDA stiff arms Evo­lus' ri­val to Al­ler­gan’s block­buster Botox, but ex­ecs promise a snap re­sponse

7 years ago

Pfiz­er fi­nal­ly fin­ish­es a 3-year reg­u­la­to­ry odyssey, bag­ging an FDA OK for 1st Epogen knock­off

7 years ago

HHS Sec­re­tary Azar pitch­es nam­ing and sham­ing tac­tics on drug price cam­paign, sin­gling out Cel­gene's Revlim­id

7 years ago

Trou­bled aTyr ax­es 30% of its staff as it wipes a pre­clin­i­cal slate clean

7 years ago
R&D

Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

7 years ago
R&D

Trump's 'sweep­ing ac­tion' to low­er drug prices mocked by an­a­lysts as re­lieved in­vestors trig­ger ral­ly in Big Phar­ma stocks

8 years ago

Sen­a­tors Wyden, Mur­ray launch No­var­tis probe: 'What Amer­i­ca has seen here rais­es the specter of cor­rup­tion'

8 years ago

La Jol­la grabs $125M roy­al­ty deal to back drug launch, fund R&D

8 years ago

Akcea, Io­n­is win over most FDA ex­perts to their rare dis­ease drug volane­sors­en, vast­ly im­prov­ing odds of suc­cess

8 years ago

Iron­wood pleas with in­vestors: Don't give us Alex Den­ner

8 years ago

Genen­tech al­lies with a metage­nomics up­start in New York on a dis­cov­ery deal jam packed with biobucks

8 years ago

Stormy Daniels’ lawyer: No­var­tis made $400K in 'sus­pi­cious' pay­ments to Trump at­tor­ney Michael Co­hen

8 years ago

Io­n­is, Akcea team face some tough ques­tions on safe­ty as FDA in­sid­ers pon­der risks linked to volane­sors­en

8 years ago
First page Previous page 297298299300301302303 Next page Last page
A service from the Financial Times